Lexcura Clinical Insights

GLP-1 medications have changed the treatment of type 2 diabetes and obesity, and semaglutide has been shown to reduce heart attack and stroke risk in high-risk patients. These powerful drugs also carry real risks. They include severe gastrointestinal effects, gastroparesis, ileus, pancreatitis, gallbladder disease, and aspiration during anesthesia. There is also a growing concern about sudden vision loss from a condition called NAION.
In this episode of Lexcura Clinical Insights, Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, looks at GLP-1s from both the clinical side and the legal side. She explains how these drugs work and where the risks come from. She then walks through the federal gastroparesis litigation and the court's requirement for a gastric emptying study, the newer vision loss MDL, and the gap between U.S. labeling and international safety warnings. She also covers the separate liability questions raised by compounded GLP-1s. Michelle closes with a five-point framework for reviewing GLP-1 medical records: the prescribing decision, the source and dose of the drug, the symptom timeline, the diagnostic workup, and other conditions or medications that could explain the injury.
Learn more at lexcurasummit.com.

Long-term care facilities now use predictive systems that flag fall risk, worsening pressure injuries, early deterioration, medication interactions, and gaps between staffing and resident acuity. When a resident is harmed, those timestamped alerts, override logs, and audit trails go into discovery and shape the expert testimony. The standard of care hasn't changed, but what can be seen in the record has.
In this episode of Lexcura Clinical Insights, Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, walks through her American Health Law Association article, When AI Becomes Evidence: Admissibility and Governance Risk in Long Term Care Litigation. She explains how AI reaches the courtroom through expert testimony under Rule 702, and why the real risk lies in the leap from alert to conclusion, not in the algorithm itself. She covers the analytical-gap warning from General Electric v. Joiner, why venue matters under Daubert or Frye, and what a good reconciliation entry should show. She also explains how the federal long-term care rules in 42 CFR Part 483, and corporate oversight principles under Caremark, raise the stakes for facility governance.
Learn more at lexcurasummit.com.

A review of recent disciplinary decisions shows a clear shift. Medical and nursing boards are focusing less on whether an outcome was bad and more on whether the clinician's reasoning can be reconstructed from the record. When the documented assessment, differential diagnosis, and plan don't form a coherent sequence, boards are more likely to find a deviation from the standard of care, even when the interventions themselves were within acceptable practice.
In this episode of Lexcura Clinical Insights, Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, walks through her American Health Law Association article, How Medical Boards Are Scrutinizing Clinical Reasoning: A Guide for Health Care Attorneys. She explains two patterns emerging in board actions. The first is the "silent pivot," a change in clinical direction with no documented reason behind it. The second is backward-tracing analysis, where reviewers follow an adverse outcome back to earlier points where risk was underestimated. Michelle then covers what this means for attorneys: assessing exposure beyond discrete deviations, choosing experts who can reconstruct clinical reasoning step by step, and preparing a defense that addresses both the care and the logic behind it.
Learn more at lexcurasummit.com.

A printed medical record can look complete while the electronic health record keeps its own separate chronology. Audit data can show when a note was created, edited, signed, or viewed, and by whom. Those details can decide a case when the timing of treatment, the authorship of an entry, or the completeness of the record is in dispute.
In this episode of Lexcura Clinical Insights, Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, walks through her American Health Law Association article, When the Audit Trail Becomes the Case. She explains why an "audit trail" isn't one standard report, and why opening a chart doesn't prove a clinician saw a result. She also covers why a late signature doesn't prove late care. Michelle reviews the New York decisions in Vargas v. Lee, Punter, Heinrich, Wright v. Stephens, and the April 2026 ruling in Harms v. Lewis. Together they show that courts want audit data tied to a disputed fact and explained by a knowledgeable witness. She closes with practical guidance for requesting and responding counsel on preservation, production format, and a four-question framework for early case assessment.
Learn more at lexcurasummit.com.

RegalCare Management Group and RegalCare Management 2.0, together with owner Eliyahu Mirlis and executive Hector Caraballo, have agreed to pay $1 million to resolve False Claims Act allegations involving skilled nursing facilities in Massachusetts. The government alleged that from 2018 to 2023 the companies billed for skilled rehabilitation therapy that was medically unreasonable and unnecessary. It also alleged that facility records were changed to support Ultra High RUG billing without a patient assessment behind it, and that claims went out before the assessment forms were finished. The case started as a qui tam whistleblower complaint, and the whistleblower will receive $165,000 of the settlement.
In this episode of Lexcura Clinical Insights, Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, breaks down the case from the clinical side. She explains how Resource Utilization Groups, the MDS, and therapy minutes drive skilled nursing reimbursement, and where in the chart a pattern like this becomes visible. For attorneys handling long-term care, fraud, or whistleblower matters, this episode shows how clinical documentation becomes evidence.
Learn more at lexcurasummit.com.

On August 31, 2026, CMS cancelled about 315,000 ACA Marketplace policies covering more than 760,000 people. The agency called the enrollments unauthorized: they were completed with help from an agent or broker, lacked verified citizenship or immigration documentation, and the insurers couldn't find any claims or reach the consumer. Weeks later, CMS put a stop to new agent and broker registrations on the federal Marketplace for plan year 2027 and issued an interim final rule that tightens consent, identity verification, and documentation requirements.
In this episode of Lexcura Clinical Insights, Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, walks through what the action means for attorneys. She covers who was affected, how health plans will handle subsidy recoupment, what the new rule asks of brokers, and where coverage disputes, broker liability claims, and gaps in care are most likely to show up. With 2027 open enrollment starting November 1, this is the context attorneys need before those cases reach their desks.
Learn more at lexcurasummit.com.

When a hospital’s electronic systems go down, patient care continues—but access to records, orders, test results, and communication may change. In this episode of Lexcura Clinical Insights, Michelle Carroll explores how attorneys can examine the clinical impact of a downtime event without assuming that the disruption itself proves a failure of care.
Using a fictional case, she explains how to define which systems and functions were unavailable, locate temporary records, distinguish when an event occurred from when it was documented, and trace a test result through communication to clinical response. The discussion also addresses medication safety, handoffs, recovery and reconciliation after systems return, and how to assess whether a particular delay mattered to the patient.
Michelle also discusses the limits of a clinical review when technical, organizational, or legal questions require other expertise. The episode references federal preparedness resources, including HHS cybersecurity performance goals and the 2025 SAFER Guide on contingency planning.
This episode is educational and is not medical, legal, technical security, or treatment advice.

In Episode 66 of Lexcura Clinical Insights, Michelle Carroll, Founder and CEO of Lexcura Summit, explores how attorneys can evaluate sepsis by following the patient’s changing condition over time. Using a fictional emergency department case, she discusses baseline health, evolving signs, communication, test-result availability, treatment orders versus administration, reassessment, escalation, and transfer.
The episode distinguishes a diagnosis label from the care delivered and explains why a chronology alone does not establish a breach or prove causation. It considers treatment in the context of the patient’s other conditions, imaging, the suspected infection source, and evidence that may support or challenge a causal connection.
For attorneys and healthcare professionals, the focus is a careful, patient-specific review of what the team knew, when information became actionable, and how the response unfolded. This episode is for educational purposes only; it is not medical or legal advice or a treatment protocol. The case is fictional.

In Episode 65 of Lexcura Clinical Insights, Michelle Carroll examines how to evaluate staffing pressure when a patient’s care moves between settings. Using a fictional hospital-to-skilled-nursing transfer that ends in a fall, she looks at what the receiving team knew, what support the patient needed, and how the handoff shaped the decisions that followed.
The episode explores how to interpret staffing records in light of a patient’s actual care needs; investigate unclear medication instructions; consider observations from family members; and trace reassessment and escalation in the record. It also explains why a documentation gap is not automatically proof of a care gap—and why a staffing concern must be connected to a specific task, time period, and plausible effect on the patient.
This educational discussion is intended for attorneys and healthcare leaders. The case example is fictional; the episode is not medical or legal advice.

A test is ordered. The result becomes available. Did the right person see it—and did the recommended follow-up happen?
In Episode 64 of Lexcura Clinical Insights, Michelle Carroll explores how to evaluate test-result follow-up in a delayed diagnosis case. Using a fictional case involving an incidental imaging finding, she traces the steps between the report and the patient’s next care: how the result was communicated, who was expected to act, whether the patient received a clear plan, and what the records show about whether follow-up was completed.
The episode also examines imaging analysis, the limits of the available record, and how to consider barriers to follow-up without jumping to conclusions about patient behavior. Michelle then discusses how to assess the possible effect of a delay while making assumptions and unanswered questions clear.
This episode is for educational purposes and does not provide medical or legal advice. The case example is fictional.